ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) shares saw an uptick in trading volume on Thursday . 1,055,997 shares changed hands during trading, an increase of 315% from the previous session’s volume of 254,698 shares.The stock last traded at $0.62 and had previously closed at $0.56.

Separately, ValuEngine upgraded shares of ContraVir Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, November 1st.

ContraVir Pharmaceuticals (NASDAQ:CTRV) last issued its quarterly earnings results on Tuesday, August 14th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter.

COPYRIGHT VIOLATION NOTICE: “ContraVir Pharmaceuticals (CTRV) Sees Unusually-High Trading Volume” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2018/11/10/contravir-pharmaceuticals-ctrv-sees-unusually-high-trading-volume.html.

ContraVir Pharmaceuticals Company Profile (NASDAQ:CTRV)

ContraVir Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. It engages in the development of TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B; and CRV431, a novel drug candidate for the treatment of chronic HBV infection.

Read More: Closed-End Mutual Funds (CEFs)

Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.